ArticleMedical decision making : an international journal of the Society for Medical Decision Making2025
Impact of Limited Sample Size and Follow-up on Partitioned Survival and Multistate Modeling-Based Health Economic Models: A Simulation Study.
Article in Medical decision making : an international journal of the Society for Medical Decision Making, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A computational framework and software tool for generating complex survival data with predefined censoring rates in simulation studies.BMC medical research methodology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BackgroundEconomic models often require extrapolation of clinical time-to-event data for multiple events. Two modeling approaches in oncology that incorporate time dependency include partitioned survival models (PSM) and semi-Markov decision models estimated using multistate modeling (MSM). The objective of this simulation study was to assess the performance of PSM and MSM across datasets with varying sample size and degrees of censoring.MethodsWe generated disease trajectories of progression and death for multiple hypothetical populations with advanced cancers. These populations served as the sampling pool for simulated trial cohorts with multiple sample sizes and various levels of follow-up. We estimated MSM and PSM by fitting survival models to these simulated datasets with different approaches to incorporating general population mortality (GPM) and selected best-fitting models using statistical criteria. Mean survival was compared with "true" population values to assess error.ResultsWith near complete follow-up, both PSMs and MSMs accurately estimated mean population survival, while smaller samples and shorter follow-up times were associated with a larger error across approaches and clinical scenarios, especially for more distant clinical endpoints. MSMs were slightly more often not estimable when informed by studies with small sample sizes or short follow-up, due to low numbers at risk for the downstream transition. However, when estimable, the MSM models more commonly produced a smaller error in mean survival than the PSMs did.ConclusionsCaution should be taken with all modeling approaches when the underlying data are very limited, particularly PSMs, due to the large errors produced. When estimable and for selections based on statistical criteria, MSMs performed similar to or better than PSMs in estimating mean survival with limited data.HighlightsCaution should be taken with all modeling approaches when underlying data are very limited.Partitioned survival models (PSMs) can lead to significant errors, particularly with limited follow-up. Incorporating general population mortality (GPM) via internal additive hazards improved estimates of mean survival, but the effects were modest.When estimable, decision models based on multistate modeling (MSM) produced similar or smaller error in mean survival compared with PSM, but small samples or limited deaths after progression produce additional challenges for fitting MSMs; more research is needed to improve estimation of MSMs and similar state transition-based modeling methods with limited data.Future studies are needed to assess the applicability of these findings to comparative analyses estimating incremental survival benefits.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.